Efficacy and safety of intra-aortic balloon pump in acute myocardial infarction with cardiogenic shock phase B

Abstract Objective This study was designed to evaluate intra-aortic balloon pump supports interventional therapy in acute myocardial infarction with cardiogenic shock phase B. Methods Two hundred and twenty patients with acute myocardial infarction with cardiogenic shock phase B treated in our hospital from January 2019 to December 2022 were divided into two groups: control group (110 patients receiving interventional therapy) and observation group (110 patients receiving interventional therapy supported by IABP). The length of stay, cardiac function indexes, MACE events and the occurrence of adverse reactions were compared between the two groups. Results There was no statistically significant difference in general data between the two groups (P > 0.05), no statistically significant difference in cardiac function indexes before treatment (P > 0.05), no statistically significant difference in TIMI blood flow level 3 standards and various slow blood flow and non-reflow phenomena between the two groups (P > 0.05). After treatment, left ventricular ejection fraction (LVEF), cardiac output (CO) and cardiac index (CI) in observation group were significantly higher than those in control group, while cardiac function grade, length of stay, N-terminal B-type diuretic pronatriuretic peptide (NT-proBNP), left ventricular work (LVW) and peripheral vascular resistance (PVR) in observation group were significantly lower than those in control group, with statistical significance (P < 0.05). Conclusion IABP supported interventional therapy showed obvious advantages in patients of acute myocardial infarction with cardiogenic shock phase B, with significant improvement in cardiac function, decrease in length of stay, and no increase in the incidence of MACE events and adverse reactions. The early clinical application is worthy of consideration.